| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 97.80 | 1.8% | 16.6% |
| Total Income | 97.80 | 1.8% | 16.6% |
| Expenditure | 56.43 | 0.6% | 8.1% |
| PBT | 47.97 | 2.5% | 61.1% |
| Net Profit | 79.37 | 107.1% | 192.0% |
| OPM | 42.30% | 1.38pp | 15.55pp |
| NPM | 81.15% | 41.24pp | 48.73pp |
| EPS | 2.74 | 106.0% | 188.4% |
Krystal Biotech Announces Q3 2025 Financial Results
04 May 2026 · 4 May, 8:17 am
Summary
Krystal Biotech, Inc. announced its financial results for the quarter ending September 30, 2025, in a press release issued on November 3, 2025. The press release is included as Exhibit 99.1 to the Form 8-K filing. The information regarding the financial results is not considered "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934.
Key Highlights
- 1
Krystal Biotech announced its financial results for the quarter ending September 30, 2025.
- 2
A press release with the company's financial results was issued on November 3, 2025.
- 3
The press release is attached as Exhibit 99.1 to the 8-K filing.
Informational and educational content only. Not investment advice.